Accession PRJCA024687
Title A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma
Relevance Medical
Data types Exome
Genome sequencing
Organisms Homo sapiens
Description This study is a multi-center, open-label, single-arm phase I clinical study of LP-108. Patients with relapsed or refractory chronic lymphocytic leukemia (CLL, arm A) and other B cell non-Hodgkin's lymphoma (NHL, Arm B). Each arm has a dose escalation phase (phase Ia) and expansion phase (phase Ib). During the dose escalation phase, the primary objectives are to define dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and to explore a recommended phase II dose. Dose escalation is based on the classic "3 + 3" design, while accelerated titration is applied to the initial lower doses. After the RP2Ds are determined, additional patients will be enrolled in the expansion phase to further evaluation the safety, PK and preliminary efficacy of LP-108, each therapy can enroll 12-20 subjects.
Sample scope Multiisolate
Release date 2024-03-26
Grants
Agency program Grant ID Grant title
Guangzhou Lupeng Pharmaceutical Co., LTD. N/A
No funding support
Submitter Zhangjie Jiang (zjiang@lupengbio.com)
Organization Guangzhou Lupeng Pharmaceutical Co., LTD.
Submission date 2024-03-26

Project Data

Resource name Description